Molecular analysis suggests oligoclonality and metastasis of endometriosis lesions across anatomically defined subtypes.

Running title: clonality and metastasis in endometriosis

Teresa H. Praetorius[1,2], Anna Leonova[2,3], Vivian Lac[2], Basile Tessier-Cloutier[2,4], Janine Senz[2], Tayyebeh M. Nazeran[2], Martin Köbel[5], Marcel Grube[1], Bernhard Kraemer[1], Paul J. Yong[2,3,6], Stefan Kommoss[1*], Michael S. Anglesio[2,3*]

Affiliations:

1) Department of Women's Health, Tübingen University Hospital, 72076 Tübingen, Germany
2) British Columbia's Gynecological Cancer Research Program (OVCARE), University of British Columbia, Vancouver General Hospital, and BC Cancer, Vancouver, BC, Canada, V5Z 4E6
3) Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada, V6H 3Z6
4) Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, Canada, V5Z 1M9
5) Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, Canada, T2N 2T9
6) BC Women's Centre for Pelvic Pain & Endometriosis, BC Women's Hospital and Health Centre, Vancouver, Canada, V6H 3N1

*Corresponding Authors (These authors contributed equally to this work):

Dr. Michael S. Anglesio, PhD
m.anglesio@ubc.ca; University of British Columbia, Robert HN Ho Research Centre; 2660 Oak Street, Vancouver, BC, Canada. V6H 3Z6

Prof. Dr. med. Stefan Kommoss
stefan.kommoss@med.uni-tuebingen.de; Department of Women's Health, Tübingen University Hospital, Calwerstraße 7, 72076 Tübingen, Germany

Abstract

Endometriosis symptoms are heterogeneous with controversy on whether it constitutes a single disease or multiple distinct types. Our previous work found recurrent somatic cancer-driver alterations in endometriosis; however, these have not been found ubiquitously. A handful of cases spread across studies also suggest mutations might be shared (clonal) between lesions of the same type. As current classification systems correlate poorly with symptoms or outcomes, somatic genomics may improve the current system. Here, we investigate heterogeneity of somatic cancer-driver mutations within patients and across endometriosis types.

We examined anatomically distinct types of endometriosis (ovarian, deep infiltrating, and superficial endometriosis) in 27 individual patients all of whom had at least two types of endometriosis. Specimens were analyzed using high-sensitivity targeted sequencing with orthogonal validation from droplet digital PCR and mutation-surrogate immunohistochemistry.

Results found 13/27 patients had informative somatic driver mutation in endometriosis, 9/13 had identical mutations across distinct lesions. Endometriomas tended to have a potential for higher mutational load, and this often resulted in functionally redundant driver mutations in same gene within the same lesions.

Our data are consistent with clonality across endometriosis lesions regardless of subtype. Further the finding of redundancy in mutations with the same gene and lesions is also consistent with endometriosis representing an oligoclonal disease with dissemination likely to consist of multiple epithelial clones travelling together. this suggests the current anatomically defined classification of endometriosis does not fully recognize the etiology of the disease. A novel classification should take into account genomic and other molecular features. These findings could further contribute to development of a more personalized endometriosis diagnosis and care.

Introduction

Endometriosis is a chronic estrogen-dependent inflammatory disease defined by the presence of endometrial epithelial glands and stroma outside the uterine lumen and a small but significant risk of malignant transformation (1-3). It is estimated to affect up to 10% of biological females of reproductive age and can result in severe adverse effects on quality of life and productivity (4, 5). Clinical symptoms of endometriosis are diverse and include pelvic pain, dysmenorrhea, dyspareunia, and infertility (2, 6). Three major anatomically described types of endometriosis are recognized: superficial peritoneal endometriosis (EM), deep infiltrating endometriosis (DIE) and ovarian endometriomas (OMA). In addition, rare types such as mass forming/tumorous or

iatrogenic forms also exist. Current classification systems such as the revised American Society for Reproductive Medicine (rASRM) scoring system and the ENZIAN classification for DIE are useful in documenting surgical findings in a standardized manner. However, they poorly correlate with the severity of symptoms and fail to provide a prognostic tool concerning the treatment outcome for pain or infertility (7, 8). Likewise, classification and staging of endometriosis are based on clinical findings and surgical presentation and do not include any information about the molecular potential or microenvironment of these lesions.

Recent studies have now shown that multiple forms of endometriosis harbor somatic cancer-driver alterations including recurrent activating changes in *KRAS, PIK3CA, ARID1A* and others (9-11). While it appears the underlying malignant potential for the vast majority of lesions, despite the presence of recurrent driver mutations, remains low (6), their ultimate function in the pathobiology of endometriosis remains unclear. These findings are particularly important to monitoring disease since somatic alteration could be therapeutically targeted or tracked to examine etiology and potential disease dissemination. The concept that endometriosis disseminates is not novel. Endometriosis frequently presents with multiple anatomical sites affected by lesions(12, 13); recent findings confirm a high rate of coexistence between OMA, EM, and DIE where only 2.3% of study had isolated OMA (12). Along with current etiology largely attributing an

origin to endometrial tissues, all endometriosis lesions may well have disseminated from a eutopic point of origin. This highlights the importance of studying the mechanisms of clonal dissemination and metastasis of endometriosis (11, 13, 14). Nonetheless, there is little objective evidence in support of widespread clonal dissemination of endometriosis tissues.

Clinical presentation of endometriosis is heterogeneous and it is controversial whether endometriosis constitutes one disease entity or whether independent types with different underlying pathogenesis exist (15). As noted above somatic alteration could be used to examine the spread and distribution of distinct endometriosis clones within a given individual. Here we explored the potential clonal relationship of endometriosis from 27 patients with multiple anatomically separated lesions, and each having at least two distinct types of endometriosis. Our initial objective was assessment of clonality at the level of endometriosis anatomically described types, asking questions such as: are mutations frequently shared between lesions and/or between lesion types. If they are not, this would suggest each anatomically defined type represents a unique disease. If they are this would indicate plasticity between types and/or that our understanding of endometriosis types is currently insufficient.

Materials and Methods

Experimental subject details

Formalin-fixed and paraffin-embedded (FFPE) archival tissues from 27 patients from the Tübingen University Hospital, Germany were included. Inclusion criteria included histopathological diagnosis of endometriosis, presentation of two or more types of endometriosis (deep infiltrating, and/or superficial, and/or ovarian endometrioma) in distinct anatomical locations, and lesions estimated to be of sufficient size for macrodissection. Patients with a history of, or co-existing, gynecological cancer were excluded. Experiments were done at the University of British Columbia and the University of Calgary. The project was conducted in compliance with the Canadian Tri-Council Policy Statement on Ethical Conduct for Research Involving Humans (TCPS2, 2018), effort to obtain written informed consent was exercised for all patients. Specimen from non-contactable patients (lost contact/deceased) treated more than 5 years before the start of the study were included under institutionally approved waiver of consent (Tübingen University Hospital Research Ethics Board). All institutions approved use of materials and associated clinical data through local research ethics boards.

Sample processing and DNA extraction

FFPE specimens were sectioned onto glass slides, stained with dilute hematoxylin and eosin, and manually enriched for endometriosis glands and stroma by manual microdissection as described previously (10, 16). DNA was extracted using the

ARCTURUS® PicoPure® DNA Extraction Kit (ThermoFisher Scientific, USA) and quantitated using the Qubit 2.0 Fluorometer (ThermoFisher Scientific, USA).

Targeted sequencing

DNA (45-75ng) was sequenced using a proprietary hypersensitive cancer hotspot sequencing panel: FIND IT™, version 3.4 (Canexia Health, Canada) (9, 10). This assay includes hotspots from 33 genes (10, 16) (Table S1). Mutations were considered “true”, if they were genuine hotspot mutations targeted by the FIND IT assay and previously reported in the Catalogue of Somatic Mutations in Cancer (COSMIC) (17), as well as prior observations with validation (9, 10), including a probability score >0.8 and a variant allele frequency (VAF) >0.8% (see Table S2A).

Validation via droplet digital PCR

Somatic mutations identified by targeted sequencing were orthogonally validated through droplet digital polymerase-chain-reaction (ddPCR) assays. In addition, selected alterations were tested by ddPCR in all available lesions from a given patient if they were observed either in any one lesion from a given patient (subjected to the FIND IT panel assay), regardless of the results obtained in other panel-tested lesions from the same patient and including any specimens from the same patient that were initially omitted from panel testing due to low DNA yield. Using previously established methods (10, 16), extracted DNA was pre-amplified for targets over 10 cycles then diluted before assembling the

ddPCR assay. Droplets were generated using the QX200 Droplet Generator (Bio-Rad Laboratories, USA), amplified by thermal cycling, and quantified using the QX2000 Droplet Reader (Bio-Rad Laboratories, USA). As above alterations were considered "true" if they passed the above noted probability and VAF thresholds for targeted sequencing or were detected using ddPCR above a droplet count set at the average of the negative control specimens plus 3 times the standard deviation of negative controls the relevant assay. See Table S3 for primer/probe details.

ARID1A, PTEN and p53 Immunohistochemistry

Immunohistochemistry (IHC) assays for ARID1A (18) , p53 (19, 20) and PTEN (10, 16) (Table S3) were used as surrogate for somatic alterations following established standards for staining and scoring. ARID1A was stained on Dako Omnis automated immunostainer (Agilent Technologies, USA) or Ventana BenchMark Ultra autostainer (Ventana Medical Systems, USA) the ARID1A rabbit polyclonal antibody, HPA005456 (Sigma-Aldrich). PTEN was stained on Ventana Discovery Ultra (Ventana Medical Systems, USA) using the rabbit monoclonal antibody, 138G6 (Cell Signaling, USA). p53 was stained on Dako Omnis (Agilent Technologies, USA) using the p53 mouse monoclonal antibody DO-7 (GA61661-2; Agilent Technologies, USA). Slides were scored by pathologists TMN, and/or BTC, and/or MK.

Calling Criteria

Calling criteria was applied to all detected alterations as noted above, including a probability score >0.8 and VAF >0.8% for panel sequencing and individual droplet count thresholds for each ddPCR assay(10, 16).

Immunohistochemistry assays were performed and scored according to established standards, briefly ARID1A loss if nuclear staining was absent in endometriosis epithelium cells and internal control (stroma) was intact (18). Mutant p53 (p53abn) if high intensity positive staining was observed in 10 or more adjacent cells in the epithelial cyst wall of endometriosis or complete absence of staining in the entire cyst wall, while maintaining a normal type pattern in surrounding tissue (19, 20). PTEN loss if cytoplasmic and nuclear staining was absent in endometriosis epithelium cells and internal control (stroma) was intact (10, 16).

Statistics

Student's t-test was performed to compare the affected genes and lesion types. However, given our limited sample size, they remained non-significant.

Results

We examined 73 endometriosis lesions from 27 patients with a mean age of 34.9 years (23-45 years; Table S2; Figure S1). 53 lesions were subjected to panel-based sequencing with validation of selected alteration by ddPCR, 6 additional samples included in

ddPCR validation only. In cases with sufficient material, lesions were also subjected to mutation surrogate IHC for PTEN (66 interpretable), ARID1A (66 interpretable) and p53 (47 interpretable). A total of 27/59 (45.8%) lesions from 13/27 (48%) cases were confirmed to have identifiable somatic cancer-driver mutations. It should be noted that lesion with mutations observed near, but below, our positive detection thresholds were considered negative, as were alteration which appeared above threshold in panel sequencing data but failed to exceed detection threshold in ddPCR. For example, in a 14th case panel testing suggested alteration but these fell below detection threshold at the ddPCR stage (case 7; Table S2). Nonetheless, potential interpretation for sub-clonal/sub-detection threshold alterations is discussed in a limited context where relevant.

Amongst the panel screened lesions, we found nearly half of the tested cases had at least one mutation; where identical assays were applied, *PIK3CA* alterations were the most common (27 hotspot mutations, affecting 12/53 lesions in 6 cases), followed by *KRAS* (16 hotspot mutations, affecting 15 lesions in 6 cases) and *CTNNB1* (10 hotspot mutations, affecting 7/53 lesions in 4 cases; Figure 1). In contrast to the overall frequency of alterations more lesions were affected by KRAS alteration overall. This trend was the same regardless of lesion type (Figure 1D) or if summarizing by fraction of affected cases (Figure 1E). Further, OMA tended to have a higher proportion of lesions affected by somatic cancer-

driver alterations and subsequently higher mutation load than other lesion types (Figure 1, Table S2).

Alterations were less frequently observed in *NRAS* (6 mutations, 6/53 lesions, 4 cases), *ERBB2* (2 mutations, 2/53 lesions, 1 case) and *EGFR* (2 mutations, 2/53 lesions, 2 cases). Although our cohort had insufficient numbers to support strong associations, we noted many lesions, predominantly amongst OMA, contained multiple mutations in the same genes. OMA also tended to have higher mutational burden on average (amongst our screened panel mutations). No samples had identifiable p53-abnormal staining pattern (0/47 lesions), PTEN loss was observed in 5 cases (8/66 lesions), and ARID1A loss was observed in 1 case (2/66 lesions).

Immunohistochemical data is inconclusive with respect to clonality, and similar abnormal patterns were considered in support of mutation findings. Our mutation data suggested a single *TP53* alteration but no abnormal p53 pattern was observed by IHC, we considered this as a false positive (case 22; Table S2A). We observed no *PTEN* mutations in sequencing data despite evidence of loss in PTEN protein expression by IHC in 8/66 lesions (Table S2B), however only a small number of hotspots are covered in panel sequencing. In one case (case 2) with PTEN loss in multiple lesions other somatic (clonal) point mutations were shared between the PTEN-loss affected lesions (Table 1; Table S2A). Case 3 showed loss of ARID1A protein

consistent with loss-of function somatic mutation (18) in both an EM and OMA samples from this patient (Figure 2). Unfortunately, insufficient tissue was available to validate any mutation in the EM sample, however, the *PIK3CA* (p.Met1043Ile) and *KRAS* alterations were shared across all other lesions from this case. Altogether we observed clonality between at least two endometriotic lesions in 8 out of 13 informative cases (Table S2A; Figure S2).

For ease in presenting results details we have divided informative cases into two categories. Simple cases, with only one or two altered genes and/or one or two informative lesions, and complex cases, with larger numbers of alterations across lesions and lesions with functionally redundant mutations.

<u>Simple cases</u>

We annotated 7 cases as simple (Table 1) based on presence of up to 2 alterations and no functionally redundant (i.e. equivalent activating change resulting from different nucleotide and/or amino acid substitution in the same gene) mutations seen in same lesion. We identified and validated shared mutations across multiple lesions and different types in 3 cases (Figure S2). Case 6 shared mutations in *PIK3CA* between EM and DIE. The other two cases shared mutations in *KRAS*. Case 19 shared a p.Gly12Ser mutation between an OMA and a DIE. Case 21 shared a p.Gly12Asp between an OMA and three different DIE lesions.

In 4 cases mutations were uninformative with respect to clonality (Figure S2), 3 of which had mutations observed in only a single lesion (*KRAS* or *EGFR*). In the last (Case 9) we detected different mutations in the lesions, consisting of different *KRAS* alterations as well as one *PIK3CA* alteration - none shared between lesions.

Complex Cases

All six cases in this complex category (Table 1) showed evidence of a clonal relationships between lesions and in each case at least one lesion showed multiple functionally redundant hotspot alterations (Figure S2; Figure 2 and 3). In one case we observed identical somatic alterations between EM and DIE lesions (case 13), in 4 cases between DIE and OMA (cases 1, 2, 3, 8; Figure 2) and in one case between all three types (case 4; Figure 3). Functional redundancy was most common with *PIK3CA*, seen in 12 lesions across 5 cases. Up to 5 simultaneously observed activating changes in *PIK3CA* were validated in a single lesion (case 2). In 4/5 cases with *PIK3CA* mutations we further observed co-existing alterations in *CTNNB1*, where at least one was shared across multiple sites/types within the affected patient. In 3/4 cases redundancy in *CTNNB1* was seen with up to 3 simultaneously observed alterations in the same lesion (case 1 OMA; case 2 DIE; and case 4 shared between DIE and EM). The fourth case had only a single observed (*PIK3CA*) co-existing *CTNNB1* alteration shared between an OMA and a DIE (case 8). A single complex case with a *PIK3CA* alteration had no co-existing *CTNNB1*

alterations, at least within our panel assay and therefore no further testing by ddPCR was done. A single case (Case 13) lacking *PIK3CA* alteration did have multiple redundant *CTNNB1* alterations, with at least one shared between DIE and EM (an OMA specimen from the same case had insufficient material for testing).

KRAS alterations were seen in 5 of 6 complex cases, only case 1 in this category showed multiple redundant activating changes (p.Gly12Val in DIE, p.Gly12Ser in both DIE and OMA). This particular case also had multiple redundant mutations in *PIK3CA* (4/4 shared), and *CTNNB1* (3/3 shared), as well as an *NRAS* (shared) alteration. As *PIK3CA*, *CTNNB1* and *KRAS* alteration were all relatively common we saw co-existence between these in 3/6 cases. The single case (Case 13) that lacked *PIK3CA* alterations had both *CTNNB1*, *EGFR* and *ERBB2*, shared between DIE and EM. A *KRAS* mutation was detectable in this case only in the DIE.

NRAS alteration were detected in 4 of 6 complex cases, no case showed multiple redundant alterations of *NRAS* itself but overlaps with *KRAS* mutations were present. In 3 cases (Cases 1, 2, 8) an *NRAS* alteration was shared between an OMA and a DIE lesion. In case 4 we detected one *NRAS* alteration shared between an OMA, a DIE lesion and an EM.

ERBB2 alterations were detected in 2 of 6 complex cases, one alteration shared between an OMA and two DIE lesions (case 3)

as well as the shared mutation in case 13 as noted above. An *EGFR* alteration was also shared between the two analyzed lesions in case 13.

Discussion

We examined a total of 73 lesions from 27 individuals affected by endometriosis, we focused on within patient heterogeneity – a largely overlooked feature amongst current genomic studies on endometriosis. Cases were specifically selected to have multiple anatomical sites affected as well as multiple “types” of endometriosis including EM, DIE and OMA. Using a high-sensitivity, and error-correcting, sequencing technology followed by validation and additional screening with ddPCR we identified somatic cancer driver alterations in lesions from 13 patients. A total of 27 lesions had at least one driver alteration, 7 lesions had more than 5.

We found evidence of identical alteration across lesions in 10 individuals, all of which spanned more than one type of endometriosis. The relatively commonplace finding of identical mutations across lesions suggests that at least a subset is clonal, sharing a common ancestor. Given our present data set the order/directionality of dissemination cannot be determined (Figures 2 and 3). We found that in 9 lesions there appeared to be multiple functionally redundant alterations, which is consistent with

individual lesions being oligoclonal. Functionally redundant mutations were seen in *PIK3CA*, *KRAS*, and *CTNNB1*. This extended to 6 of 13 cases with observed somatic alterations. In 3 of these cases the redundant alterations were identified in two or more, suggesting dissemination likely involved multiple epithelial clones traveling together.

Examining the specific prevalence of mutations across lesions we observed more *PIK3CA* mutations than any other. Amongst informative cases OMAs tended to have a higher average mutation burden, at least within our panel, with OMA lesions from cases 1, 2, 3 having multiple activating *PIK3CA* and/or *CTNNB1* (and others) driving this average mutation burden up. When examining prevalence at a per lesion or per individual level we found more lesions, and more individuals, to be affected by somatic KRAS mutations. Despite a higher mutation burden within a subset of OMAs, DIE appeared to have a wider range of mutations from our panel with *EGFR* and *ERBB2* mutations seen only in DIE.

Our study is unique in examination of a modest number of co-existing lesions. Particular strengths include enrichment of endometriosis glands and stroma, the use of proven high-sensitivity and specificity digital sequencing methods, and orthogonal validation for the majority of alterations (21). We elected to be relatively conservative in calling mutations, however, it should be noted that a number of alterations were found to be

just below detection thresholds, if a single assay was done, or both just above on panel sequencing and just below on ddPCR. In such cases we considered alteration to be negative/unvalidated. In sampling tissue for sequencing assays and subsequent ddPCR we took sequential tissue sections from a block for enrichment and analysis, often requiring re-sampling of tissue for validation. Hence, we must consider that in a small population of cells, such as a microscopic glands of endometriosis epithelium, it is possible that the proportion of mutation harboring cells changes as a specimen is sectioned such that it would genuinely yield a fraction of cells below a detection threshold in one sampling and above a detection threshold in another. If we were to be more liberal with assessment of ground-truth mutations our overall conclusion would not change though it would suggest greater complexity and more examples of oligoclonal dissemination throughout our cohort.

Potential weaknesses include the use of macrodissection instead of laser capture microdissection. In this context we cannot reliably use the variant allele frequency for anything other than binary presence or absence assessment of somatic alterations. IHC observations suggested somatic alteration were exclusive to the epithelium, similar to prior observation with laser-capture microdissection, though this was not explicitly monitored in sequencing experiments. In addition, we used only a relatively limited panel assay to screen for mutations. Therefore, while we

can make suggestions about potential lineage of samples with informative mutations, we are missing considerable data about the un-analyzed genome. Thus, this should be considered as a minimum estimate of clonality. We cannot strictly conclude that any cells or lesions (within a given patient) that do not share mutations with those found within our panel are of unrelated lineage. Nonetheless, the presence of functionally redundant alterations (multiple *KRAS, PIK3CA*, and *CTNNB1* alterations) does suggest at the very least divergence of subclones within lesions is likely.

Broad dissemination and metastasis in general are common features of advanced cancers but are not typical for a benign neoplastic disease. Endometriosis knowingly shares many characteristics with tumors, and it is also associated with the most lethal gynecologic cancer: ovarian carcinomas, where endometriosis is both a risk factor and proven precursor lesion for both endometrioid and clear cell ovarian carcinomas.

All major anatomically described types of endometriosis can harbor recurrent somatic cancer-driver alterations. Our findings validate a modest spectrum of driver alterations, as has been described previously (9, 10, 22). While single cases have been described to share alteration between lesions of the same type (9, 14), we provide considerable evidence that shared lineage between lesions is common, not only between lesions of the same type, but across anatomically defined lesion types. If we consider

the likelihood of clonal dissemination of endometriosis, then anatomical lesion type descriptions alone are insufficient and should be supplemented with molecular characterizations – albeit which features are clinically useful is not yet established.

In recent years there has been a shift away from seeing endometriosis as one disease entity. In addition to biochemical variations, considerable efforts are being applied to identify subtype-specific genomic alterations. This ongoing trajectory of thought has spiked research of endometriosis biomarkers and subtype-tailored treatment. However, here we demonstrate that sampling and comparing lesions from different individuals based solely upon anatomical classification, may yield inadequate results. Our data supports the presence of identical mutations among lesions of the same individual and suggests the clonal dissemination and metastasis mechanism of disease spreading. This underscores the need for molecular classification when designing personalized endometriosis care.

To make significant impact the next generation of endometriosis-genomic studies must apply high stringency methods, with appropriate enrichment of tissues, orthogonal validation and/or error correcting sequencing technologies, and most critically be coupled to large clinical data registries conforming to accepted standards in phenotyping data (21) - such as those promoted by WERF-EPHect (23, 24). Early studies on somatic genomics of endometriosis have suggested relatively few alterations per lesion

(9, 11, 22, 25). However, this work suggests endometriosis may have moderate genomic complexity. Any future study wishing to correlate genomic heterogeneity with the clinical phenotypic spectrum may be complex, it is not sufficiently informative to sample only one lesion per patient for mutation testing. Accurate assessment of somatic mutation profiles may require a significant fraction of lesions are excised and tested at surgery (rather than ablated without biopsy).

In addition to the already appreciated complexity of endometriosis, it has now become even more evident that disease presentation is unique and may depend on many factors. This work has also shown that OMAs had the highest mutation burden, while DIE lesions were associated with wider range of mutation. Considering previous work in the field (26-29), this data is consistent with observations that lesion microenvironment may be more permissive for expansion of multiple clones, and hence the higher risk of malignant transformation (30). DIEs might be surrounded by a more restrictive microenvironment conditions resulting in fewer clones and lower malignant potential. As a specific example of clonal expansion, we observed that multiple redundant *PIK3CA* activating mutation were prevalent in OMAs. These *PIK3CA* alterations are also common to endometriosis-associated cancers and appear necessary (in combination with ARID1A) for the generation of a representative clear cell ovarian carcinomas model in mice (31), together suggesting they are critical in

underlying malignant potential. Extraovarian microenvironment restriction on malignant potential has been suggested as a potential mechanism for the generally favorable outcomes observed in low-stage synchronous (yet metastatic) endometrioid ovarian and endometrial carcinomas – etiologies tightly linked to endometriosis(32).

As we move forward, consideration should be made to determine if patient-wide endometriosis mutation profiles should include ranking of allele frequency, dissemination/spread, clonality across lesions and anatomic types. Phenotyping clinical characteristics could also monitor eutopic endometrium (16) and pathway enrichment across mutations. Intra-lesion spatial heterogeneity (such as in a large OMA or deep nodules) may warrant study especially in relapse/persistent chronic disease and those associated with malignant progression. Simple binary assessment now seems insufficient and modeling with machine learning approaches may be paramount to identify associations between heterogeneous molecular profiles and heterogeneous clinical presentation.

Figure Legends

Figure 1: Fraction of cohort affected by somatic hotspot mutations detected in panel sequencing. (A) Overall split of cases with at least one lesions having at least one somatic cancer-driver

alteration. (B) Numbers of detected somatic mutations, split by affected gene, across our entire cohort. (C) Fraction of mutation affected lesions, split by mutation type. (D) Fraction of mutation affected lesions, split by lesion type. (E) Fraction of mutation affected lesions, summarized by fraction of affected cases.

Figure 2: Clonal relationships in Case 3 patient presenting with DIE of the vagina, DIE of the cul-de-sac, an OMA of the left ovary, and EM of the rectum. (A) Detected somatic alteration from sequencing and mutation surrogate IHC suggest identical/clonal alteration in *KRAS*, *ERBB2*, and *PIK3CA* (p.Met1043Ile) between OMA and two anatomically distinct lesions of DIE. Additional *PIK3CA* alterations are also visible in the OMA and vaginal DIE. Heterogeneous loss of ARID1A is observed in only the OMA and EM (insufficient material was available for mutation testing in EM). (B) Three possible dissemination models explaining the mutational pattern: (1) top panel illustrates a linear pattern wherein clones from the cul-de-sac travel to the vagina and acquired additional alterations in *PIK3CA*. Subsequent transfer of all clones to the ovary where subclonal-ARID1A loss occurs. It may further be speculated that the EM resulted from a transfer of clones between the vaginal DIE and OMA (as the initial site for ARID1A loss) or subsequent spread after clones established on the ovary. Given the lack of mutational data on the EM it may also be entirely independent. (2) middle panel illustrates an example where a complex set of clones exist at the ovary and only a subset of these

break-off and colonize vaginal, cul-de-sac and EM/rectal sites. Finally, (3) Lower panel illustrates parallel dissemination from the cul-de-sac lesion to both the vaginal and ovarian sites. Herein we may consider sub-threshold signal from ddPCR of p.Arg88Gln, p.Glu545Lys and p.Gly1049Ser PIK3CA alteration (Table S2) as weak evidence of emerging/undetectable clones that subsequently expand post-transfer of cells to both vagina and ovary. In this model again, the OMA acquires loss-of function ARID1A alterations. Additional possibilities may also explain the mutational patterns. (C-D-E) photomicrographs showing ARID1A IHC results including regions of loss (surrogate for loss-of function mutation; black arrows) and normal (retained nuclear staining; red arrows) in endometriosis epithelium.

Figure 3: Clonal relationships in Case 4 patient presenting with DIE of the rectum, EM of the cul-de-sac and an OMA on the left ovary. (A) Detected somatic alteration from sequencing suggest all variants are shared between DIE and EM lesions. In contrast the ovarian lesion shares only 1 *PIK3CA* and 1 *KRAS* alteration with the other two and has no (detected) unique changes. (B) Three possible dissemination models explaining the mutational pattern: (1) top panel illustrates a linear model wherein clones from the ovary travel to the rectum, expand and acquire additional alteration. Cells from the DIE containing all clones then seed the EM on the Cul-de-sac. (2) middle panel illustrates another linear model of dissemination wherein a complex clonal population at the

Rectum seed the cul-de-sac. Subsequently only a subset of these clone travel to and populate the ovary. Finally, (3) illustrates a differing model of spread wherein a complex clonal population at the Rectum seed the cul-de-sac with all clones. Only a subset with a single *PIK3CA* and *KRAS* altered clone break-off to the ovary (or alternatively only a subset with these specific alterations can colonize the ovary).

Tables

Table 1: Cohort Overview. Each cell shows the number of lesions available and tested from the noted anatomical site/type (number in brackets denote lesions were not tested in panel sequencing). Blue cell = shared alteration within case/between lesions marked by blue cells in table (cells not in blue were uninformative/did not show evidence of clonality with any other lesion from the given case), Grey lines/cases were entirely uninformative (no mutation detected in panel sequencing from any tested lesion). Abbreviations: DIE= Deep infiltrating endometriosis, EM= superficial endometriosis, OMA= endometrioma

References

1. Munksgaard PS, Blaakaer J. The association between endometriosis and ovarian cancer: a review of histological, genetic and molecular alterations. Gynecol Oncol **124**, 164-9 (2012). https://10.1016/j.ygyno.2011.10.001

2. Zondervan KT, Becker CM, Missmer SA. Endometriosis. N Engl J Med **382**, 1244-56 (2020). https://10.1056/NEJMra1810764

3. Giudice LC. Clinical practice. Endometriosis. N Engl J Med **362**, 2389-98 (2010). https://10.1056/NEJMcp1000274

4. Eskenazi B, Warner ML. Epidemiology of endometriosis. Obstet Gynecol Clin North Am **24**, 235-58 (1997).

5. Bulun SE. Endometriosis. N Engl J Med **360**, 268-79 (2009). https://10.1056/NEJMra0804690

6. Vercellini P, Vigano P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol **10**, 261-75 (2014). https://10.1038/nrendo.2013.255

7. Johnson NP, Hummelshoj L, Adamson GD*, et al.* World Endometriosis Society consensus on the classification of endometriosis. Hum Reprod **32**, 315-24 (2017). https://10.1093/humrep/dew293

8. American Society for Reproductive Medicine. Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril **67**, 817-21 (1997).

9. Anglesio MS, Papadopoulos N, Ayhan A*, et al.* Cancer-Associated Mutations in Endometriosis without Cancer. N Engl J Med **376**, 1835-48 (2017). https://10.1056/NEJMoa1614814

10. Lac V, Verhoef L, Aguirre-Hernandez R*, et al.* Iatrogenic endometriosis harbors somatic cancer-driver mutations. Hum Reprod **34**, 69-78 (2019). https://10.1093/humrep/dey332

11. Suda K, Nakaoka H, Yoshihara K*, et al.* Clonal Expansion and Diversification of Cancer-Associated Mutations in Endometriosis and Normal Endometrium. Cell Rep **24**, 1777-89 (2018). https://10.1016/j.celrep.2018.07.037

12. Piriyev E, Schiermeier S, Romer T. Coexistence of endometriomas with extraovarian endometriosis and adhesions. Eur J Obstet Gynecol Reprod Biol **263**, 20-4 (2021). https://10.1016/j.ejogrb.2021.05.044

13. Exacoustos C, De Felice G, Pizzo A*, et al.* Isolated Ovarian Endometrioma: A History Between Myth and Reality. J Minim Invasive Gynecol **25**, 884-91 (2018). https://10.1016/j.jmig.2017.12.026

14. Suda K, Cruz Diaz LA, Yoshihara K*, et al.* Clonal lineage from normal endometrium to ovarian clear cell carcinoma through ovarian endometriosis. Cancer Sci, (2020). https://10.1111/cas.14507

15. Montgomery GW, Giudice LC. New Lessons about Endometriosis - Somatic Mutations and Disease Heterogeneity. N Engl J Med **376**, 1881-2 (2017). https://10.1056/NEJMe1701700

16. Lac V, Nazeran TM, Tessier-Cloutier B*, et al.* Oncogenic mutations in histologically normal endometrium: the new normal? J Pathol **249**, 173-81 (2019). https://10.1002/path.5314

17. Forbes SA, Bindal N, Bamford S*, et al.* COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res **39**, D945-50 (2011). https://10.1093/nar/gkq929

18. Khalique S, Naidoo K, Attygalle AD*, et al.* Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers. J Pathol Clin Res **4**, 154-66 (2018). https://10.1002/cjp2.103

19. Kobel M, Piskorz AM, Lee S*, et al.* Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma. J Pathol Clin Res **2**, 247-58 (2016). https://10.1002/cjp2.53

20. Kobel M, Ronnett BM, Singh N*, et al.* Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility. Int J Gynecol Pathol **38 Suppl 1**, S123-S31 (2019). https://10.1097/PGP.0000000000000488

21. Yong PJ, Talhouk A, Anglesio MS. Somatic Genomic Events in Endometriosis: Review of the Literature and Approach to Phenotyping. Reprod Sci, (2021). https://10.1007/s43032-020-00451-9

22. Noe M, Ayhan A, Wang TL, Shih IM. Independent development of endometrial epithelium and stroma within the same endometriosis. J Pathol, (2018). https://10.1002/path.5082

23. Fassbender A, Rahmioglu N, Vitonis AF*, et al.* World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonisation Project: IV. Tissue collection, processing, and storage in endometriosis research. Fertil Steril **102**, 1244-53 (2014). https://10.1016/j.fertnstert.2014.07.1209

24. Rogers PA, Adamson GD, Al-Jefout M*, et al.* Research Priorities for Endometriosis. Reprod Sci **24**, 202-26 (2017). https://10.1177/1933719116654991

25. Bulun SE, Wan Y, Matei D. Epithelial Mutations in Endometriosis: Link to Ovarian Cancer. Endocrinology **160**, 626-38 (2019). https://10.1210/en.2018-00794

26. Artemova D, Vishnyakova P, Khashchenko E*, et al.* Endometriosis and Cancer: Exploring the Role of Macrophages. Int J Mol Sci **22**, (2021). https://10.3390/ijms22105196

27. Olkowska-Truchanowicz J, Bialoszewska A, Zwierzchowska A*, et al.* Peritoneal Fluid from Patients with Ovarian Endometriosis Displays Immunosuppressive Potential and Stimulates Th2 Response. Int J Mol Sci **22**, (2021). https://10.3390/ijms22158134

28. Oda K, Hamanishi J, Matsuo K, Hasegawa K. Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management. Gynecol Oncol **151**, 381-9 (2018). https://10.1016/j.ygyno.2018.09.001

29. Lai CR, Hsu CY, Chen YJ*, et al.* Ovarian cancers arising from endometriosis: a microenvironmental biomarker study including ER, HNF1ss, p53, PTEN, BAF250a, and COX-2. J Chin Med Assoc **76**, 629-34 (2013). https://10.1016/j.jcma.2013.07.008

30. Saavalainen L, Lassus H, But A*, et al.* Risk of Gynecologic Cancer According to the Type of Endometriosis. Obstet Gynecol, (2018). https://10.1097/AOG.0000000000002624

31. Chandler RL, Damrauer JS, Raab JR*, et al.* Coexistent ARID1A-PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory

cytokine signalling. Nat Commun **6**, 6118 (2015). https://10.1038/ncomms7118

32. Anglesio MS, Wang YK, Maassen M*, et al.* Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality. J Natl Cancer Inst **108**, (2016). https://10.1093/jnci/djv428

Acknowledgements

The authors thank all the study participants who contributed to this study. We further recognize the invaluable contributions of Prof. Dr. Sara Y. Brucker for continuous support of international collaborations between the University Hospital Tübingen and the University of British Columbia, as well as PD Dr. Annette Staebler and the staff of the Institute of Pathology, University Hospital Tübingen for facilitating access to pathology archives.

Funding was provided by Canadian Institutes of Health Research (Early Career Investigator Grant in in Maternal, Reproductive, Child & Youth Health to MS Anglesio). M Köbel received support through the Calgary Laboratory Services research support fund (RS19-609). MS Anglesio is funded through a Michael Smith Foundation for Health Research Scholar Award (18274) and the Janet D. Cottrelle Foundation Scholars program (managed by the BC Cancer Foundation). This project received technical and data management support from Calgary Laboratory Services and the Genetic Pathology Evaluation Centre (GPEC). GPEC receive core support from BC's Gynecological Cancer Research team (OVCARE), and the VGH+UBC Hospital Foundation. M Köbel

was supported by internal research support (RS19-621). No funder had any role in the study design, collection of data, recruitment or participants, interpretation of results, manuscript content, or decision to publish.

Compliance with ethical standards

Conflict of interest

The authors declare no competing interests.

Ethics approval/consent to participate

All work was done in compliance with the Canadian Tri-Council Policy Statement (TCPS2 2018) on ethical conduct for research involving humans. Effort to obtain written informed consent was exercised for all patients. Specimen from non-contactable patients (lost contact/deceased) treated more than 5 years before the start of the study were included under institutionally approved waiver of consent (Tübingen University Hospital Research Ethics Board). Research Ethics Boards of all participating institutions approved the study and use of materials.

Author contributions

MSA and SK designed the study and concept. THP, MG, BK, and SK identified candidate patients and obtained consent. THP, VL, and JS processed and enriched samples and conducted molecular experiments. BTC, TMN and MK conducted and scored

immunohistochemical experiments and reviewed/confirmed endometriosis pathology. THP, JS, and MSA analyzed and interpreted data. THP, AL, and MSA wrote the original draft. PJY, BK, SK reviewed finding and all authors approved the draft manuscript. Final draft was completed by AL and MSA.

Funding

This study received funding from the Canadian Institutes of Health Research, the Michael Smith Foundation for Health Research, the Janet D. Cottrelle Foundation, and the Calgary Laboratory Services Research Support Fund.

Data availability

All data generated are available in this manuscript and supplemental documents. Access to unprocessed/raw data from the authors will be made available upon request, subject to REB approval and applicable privacy laws.


A
Cases with Mutations in Endometriosis Lesions
13
14
Harboring mutation
Not Detected in Panel
B
Mutations Detected in Panel Seq (#)
30
20
10
0
PIK3CA
NRAS
CTNNB1
KRAS
ERBB2
EGFR
C
Fraction of affected lesions
0.3
0.2
0.1
0
PIK3CA
NRAS
CTNNB1
KRAS
ERBB2
EGFR
D
Fraction of affected lesions, split by lesion type
0.45
0.4
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0
PIK3CA
NRAS
CTNNB1
KRAS
ERBB2
EGFR
OMA
DIE
EM
E
Fraction of affected cases/individuals
0.4
0.2
0
PIK3CA
NRAS
CTNNB1
KRAS
ERBB2
EGFR

Figure 1

A

Case 3 Detected Alterations					
Gene	**Hotspot**	**OMA** Left ovary	**DIE (v)** Vagina	**DIE (c)** Cul-de-sac	**EM** Rectum
PIK3CA	p.Glu545Lys	X	X		Insufficient size for sequencing
PIK3CA	p.Gly1049Ser	X	X		
PIK3CA	p.Arg88Gln	X	X		
PIK3CA	p.Met1043Ile	X	X	X	
KRAS	p.Gly12Asp	X	X	X	
ERBB2	p.Ser310Phe	X	X	X	
ARID1A IHC		Loss in atypical endometriosis			Hetero-geneous loss







Figure 2

A

Case 4 Detected Alterations				
Gene	**Hotspot**	**DIE** Rectum	**OMA** Left ovary	**EM** Cul-de-sac
PIK3CA	p.Glu542Lys	X		X
PIK3CA	p.Glu545Lys	X		X
PIK3CA	p.Gly1049Ser	X		X
PIK3CA	p.Met1043Ile	X	X	X
NRAS	p.Gly13Asp	X	X	X
CTNNB1	p.His36Tyr	X	X	X
CTNNB1	p.Gly34Glu	X		X
KRAS	p.Gly12Asp	X	X	X

B



Figure 3

Table 1 - Cohort overview

		DIE																EM											OMA			
	Case ID	appendix	bladder	cul-de-sac	left sacrouterine ligament	rectovaginal septum	rectum	right psoas	right sacrouterine ligament	right pelvic wall	left pelvic wall	right pararectal space	right fossa ovarica	sigmoid	incisional	vagina	umbilicus	bladder	cul-de-sac	rectum	right abdominal wall	right pelvic wall	left pelvic wall	right sacrouterine ligament	left sacrouterine ligament	colon	right ovary	left pararectal space	left ovary	pararectal space	right ovary	Grand Total
Complex Cases	1						1																								1	2
	2						1																								1	2
	3			1												1				[1]									1			4
	4						1												1										1			3
	8	1																				[1]		[1]					1			4
	13		1																		1								[1]			3
Simple Cases	6								1														1									2
	9	1																													1	2
	19													1																1		2
	20				1													1														2
	21		1		1	1			[1]																				1		1	6
	22				1				1										1													3
	24				1	1		1										[1]														4
Uninformative Cases	5						1																				1					2
	7														1								1									2
	10		1																							[1]						2
	11													1;[1]															[1]			3
	12		1																										1			2
	14													1															1			2
	15						1									[1]													1			3
	16					1																									1	2
	17														1										1							2
	18	1																													1	2
	23																1														1	2
	25									1													1						1			3
	26										1								[1]													2
	27								1			[1]	[1]					[1]										1				5
	Grand Total	3	4	1	4	3	5	1	4	1	1	1	1	4	2	2	1	3	3	1	1	1	3	1	1	1	1	1	10	1	7	73

Each cell shows the number of lesions available and tested from the noted anatomical site/type (number in brackets denote lesions were not tested in panel sequencing and detected only in ddPCR). Blue cell = shared alteration within case/between lesions marked by blue cells in table (cells not in blue were uninformative/did not show evidence of clonality with any other lesion from the given case), Grey lines/cases were entirely uninformative (no mutation detected in panel sequencing from any tested lesion). Abbreviations: DIE= Deep infiltrating endometriosis, EM= superficial endometriosis, OMA= endometrioma